Get the Stockscreener App
2.08
2.35%
-0.05
After Hours:
2.08
Aytu Biopharma Inc stock is traded at $2.08, with a volume of 42,698.
It is down -2.35% in the last 24 hours and down -5.02% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.13
Open:
$2.16
24h Volume:
42,698
Relative Volume:
1.24
Market Cap:
$22.33M
Revenue:
$56.60M
Net Income/Loss:
$-34.12M
P/E Ratio:
-0.4537
EPS:
-4.5844
Net Cash Flow:
$-1.36M
1W Performance:
-3.70%
1M Performance:
-5.02%
6M Performance:
-19.38%
1Y Performance:
-18.11%
1-Day Range:
$2.07
$2.1785
1-Week Range:
$2.03
$2.2094
52-Week Range:
$1.6501
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.08 | 22.11M | 56.60M | -34.12M | -1.36M | -4.5844 |
TAK
Takeda Pharmaceutical Co Adr
|
17.75 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.28 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.71 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.93 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
524.70 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Aytu BioPharma Market Sentiment - Benzinga España
Aytu Biopharma Inc (AYTU) Cash Flow - TradingKey
Aytu Biopharma Inc (AYTU) Balance Sheet - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.107|Chg%:+0.046 - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.160| - TradingKey
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aytu Biopharma Inc (AYTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Aytu BioPharma, Inc. Revenue Breakdown – NASDAQ:AYTU - TradingView
Aytu Biopharma Inc (AYTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsGap Fill Strategy - dars.gov.et
AYTU Q2 2026 Earnings: EPS Miss Slightly Wider Than Expected; Stock Rises 2.74% Amid Strategic ReviewEarnings Beat Streak - dars.gov.et
Aytu BioPharma Holds Steady Near $2.16 Amid Modest Gains – Key Levels in FocusFactor Valuation - DonanımHaber
Aytu BioPharma | SCHEDULE 13G/A: Others - Moomoo
Aytu BioPharma, Inc. (AYTU) reports Q3 loss, tops revenue estimates - MSN
Aytu BioPharma, Inc. Actuals & Estimates (NASDAQ:AYTU) - TradingView
AYTU Forecast — Price Target — Prediction for 2027 - TradingView
Aytu BioPharma, Inc. Actuals & Estimates (LSE:0A8M) - TradingView
0A8M Forecast — Price Target — Prediction for 2027 - TradingView
Aytu Biopharmato Continue Selling Existing - Moomoo
Aytu BioPharma Ends Metadate CD License With Lannett; Sell-Through Allowed After Mutual Termination - TradingView
Aytu BioPharma (AYTU) ends Metadate CD license agreement with Lannett - Stock Titan
Price to sales forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
Enterprise value to EBIT forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
Enterprise value to revenue forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
AYTU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aytu Biopharma Inc (AYTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aytu Biopharma Inc (AYTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aytu Biopharma Inc (AYTU) Institutional Confidence - TradingKey
Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AYTU: EXXUA's unique profile and RxConnect network drive strong early growth and market resilience - TradingView
AYTU: EXXUA’s unique profile and RxConnect network drive growth and resilience amid market shifts - TradingView
Aytu BioPharma (AYTU) Surges 4.2% as Shares Approach Resistance at $2.28Shakeout Pattern - newsline.com
Aytu BioPharma Inc. (AYTU) Gains 4.23% as Shares Test Key Resistance at $2.28PCR Spike - newsline.com
Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aytu BioPharma (AYTU) Slips 1.83% as Stock Tests Key Support Near $2.04WMA Signal - newsline.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AYTU Maintained by Ascendiant Capital -- Price Target Raised to $14.50 - GuruFocus
AYTU Q1 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterUpward Estimate Revision - newsline.com
Aytu BioPharma Gains 5.89% as Small-Cap Biotech Finds TractionDaily Profile - newsline.com
Aytu BioPharma Inc. (AYTU) Gains 3.3% as Shares Approach Resistance at $2.30Channel Breakout - newsline.com
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 - Hastings Tribune
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance ZoneSector ETF Flow - The Legal Advocate
AYTUAytu BioPharma Inc Stock Price and Quote - Finviz
AYTU Q1 2026 Earnings: Narrow EPS Miss Amid Limited Revenue Disclosure; Shares Edge HigherNet Income Trends - newsline.com
AYTU Q1 2026 Earnings: EPS Misses Estimates by 1.88%, Stock Declines Amid Sparse DisclosureReturn On Assets - The Legal Advocate
AYTU: EXXUA’s launch drives growth as legacy ADHD revenues decline, with strong financial footing - TradingView
AYTU Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesEarnings Trend Analysis - The Legal Advocate
AYTU Q1 2026 Earnings EPS Misses Estimates Amidst Operational ChallengesThe Legal Advocate - The Legal Advocate
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.28%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):